Hybrid Closure of Congenital Heart Disease

Related Clinical Trial
Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects The Effect of Transcatheter VSD Closure on Children’s Appetite, Hormones and Growth The Effect of Transcatheter Ventricular Septal Defect Closure on Heart Rate Variability Parameters Improving Care for Children With Congenital Heart Disease. Lifetech MFO Post-Market Clinical Follow-Up Study Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions A Phase I Study of Dexmedetomidine Bolus and Infusion in Corrective Infant Cardiac Surgery: Safety and Pharmacokinetics Optical Tissue Identification for Myocardial Architecture Measures to Lower the Stress Response in Pediatric Cardiac Surgery Cardiac Function After Transcatheter VSD Closure The Effect of Remote Ischemic Preconditioning on the Ischemic Reperfusion Injury in Infants With Ventricular Septal Defect and Pulmonary Hypertension A Trial to Evaluate the Safety and Efficacy of a Fully Degradable Ventricular Septal Defect (VSD) Closure Closure of Muscular Ventricular Septal Defects (VSDs) With the AMPLATZER Muscular VSD (MuVSD) Occluder – Post Approval Study The Cardiopulmonary Effect of Inhaled Beta-2-agonists on Adult Patients Born With Ventricular Septum Defects. Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol Optimal Timing for Repair of Left to Right Shunt Lesions Use of Ketamine Prior to Cardiopulmonary Bypass in Children Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow Transcatheter Closure Versus Surgery of Perimembranous Ventricular Septal Defects Cardiopulmonary Function in Adults Born With a Ventricular Septal Defect Longterm Outcome After Ventricular Septal Defect Closure Closure of Perimembranous Ventricular Septal Defects With The AMPLATZER® Membranous VSD OCCLUDER Hybrid Closure of Congenital Heart Disease

Brief Title

Hybrid Closure of Congenital Heart Disease

Official Title

Precision Assessment of Perioperative Effectiveness and Safety of Transthoracic Minimally Invasive Hybrid Closure for Pediatric Ventricular Septal Defects

Brief Summary

      Ventricular septal defect (VSD) is one of the most common pediatric congenital malformations.
      In recent years, in view of the rapid rise of transthoracic minimally invasive hybrid closure
      for pediatric VSD in the clinical practice, precision assessment of perioperative its
      effectiveness and safety has already become an important issue that must be solved. On the
      basis of echocardiography, integrating with characteristics associated critical care, the
      investigators focus on precision assessment of perioperative effectiveness and safety of
      transthoracic hybrid closure for pediatric VSD, compared with conventional surgical
      sternotomy repair with cardiopulmonary bypass (CPB).

Study Type


Primary Outcome

Myocardial injury as measured by cardiac troponin I serum

Secondary Outcome

 All cause mortality


Pediatric Ventricular Septal Defects


sufentanil anesthesia

Study Arms / Comparison Groups

 Off-pump hybrid closure
Description:  Hybrid closure is that a periventricular technique uses an occluding device to closure ventricular septal defects of patients through the delivery system by transthoracic minimally invasive small incision without cardiopulmonary bypass.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

January 2011

Completion Date

December 2016

Primary Completion Date

December 2016

Eligibility Criteria

        Inclusion Criteria:

          -  confirmed diagnosis of perimembranous ventricular septal defect, muscular ventricular
             septal defect, doubly committed subarterial VSD by transesophageal echocardiogram
             (TEE) with VSD size 5-12mm;

          -  no significant aortic insufficiency or aortic valve prolapse.

        Exclusion Criteria:

          -  confirmed pulmonary hypertension (systolic pulmonary arterial pressure >75mmHg or
             pulmonary vascular resistance >8.0 Wood U/m2);

          -  more than mild degree of aortic regurgitation and obvious aortic valve prolapse;

          -  preoperative congestive heart failure;

          -  other coexisting cardiac anomalies;

          -  infective endocarditis.




1 Year - 5 Years

Accepts Healthy Volunteers



Hai-tao Gu, MD, PhD, , 

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

Nanjing Medical University

Study Sponsor

Hai-tao Gu, MD, PhD, Principal Investigator, The First Affiliated Hospital with Nanjing Medical University

Verification Date

June 2017